Nanjing Vazyme Biotech News

Novizan (688105): The life sciences and biomedical sectors are growing rapidly, and overseas markets are expanding rapidly

zhongtai SecuritiesOct 31 18:47

Novi Zan (688105): Profitability ushered in an inflection point, and several large single products are expected to drive performance to usher in a new round of growth

Sep 9 15:06

Company review Novizan (688105): The inflection point of conventional upstream business has now brought new growth points to AD blood tests and GLP-1 intermediates businesses

Sep 3 00:00

Novizan (688105): Significant improvement in overall performance, AD series diagnostic products are expected to usher in commercialization

Aug 29 21:11

Novi Zan (688105): 2Q net profit turned loss into profit and quiet, waiting for the inflection point to arrive

Aug 29 00:00

Novizan (688105): Regular business continues to grow, and new products are ready to launch in many fields

May 10 00:00

Novi Zan (688105): Regular business maintains high growth, and the prototype of a platform-based enterprise with a multi-product layout is beginning to show

May 4 00:00

Novi Zan (688105) 2023 Annual Report and 2024 Quarterly Report Review: Business structure affects performance fluctuations and regular business grows steadily

Apr 28 16:31

Novi Zan (688105): Achieved profit in the third quarter of a single quarter and expected the release of new products

Mar 29 08:11

Novi Zan (688105): Open source, save money and look forward to the release of new products

Dec 28, 2023 00:00

Novizan (688105): The leader in deep-rooted molecular biological reagents is now

Nov 17, 2023 07:06

Novizan (688105): Turning a loss into a profit in the third quarter and expecting performance to resume growth

Nov 5, 2023 00:00

Novizan (688105): Expense rates improved significantly month-on-month during a period of steady, moderate and positive conventional business

Nov 4, 2023 00:00

Novizan (688105): Short-term performance is under pressure, waiting for downstream recovery

Oct 31, 2023 00:00

Novizan (688105): 3Q profit reversal, profit is expected to continue to improve next year

Oct 30, 2023 14:06

Novizan (688105): Life science business continues to improve, demand for IVD is expected to accelerate

Oct 30, 2023 00:00

Novizan (688105): Reversing losses in the third quarter and expecting continued improvement in profit

Oct 30, 2023 00:00

Nuowizan (688105): Regular business recovery is good, equity incentives show confidence in long-term development

中泰證券Sep 3, 2023 00:00

Nuowizan (688105): 23H1 performance is under short-term pressure, equity incentives show confidence in long-term development

德邦證券Aug 31, 2023 00:00

Nuowizan (688105): The launch of an equity incentive plan is yet to come

華泰證券Aug 30, 2023 00:00